Aytu Adds Late-Stage Pediatric Onset Rare Disease Asset to Development Pipeline
13 Apr 2021 //
ACCESWIRE
Aytu BioPharma Divests U.S. Rights to Natesto(R) to Acerus Pharma
01 Apr 2021 //
ACCESSWIRE
Aytu BioScience Announces Close of Merger with Neos Therapeutics
22 Mar 2021 //
BIOSPACE
Aytu BioScience Announces Close of Merger with Neos Therapeutics
22 Mar 2021 //
BIOSPACE
Aytu BioScience and Neos Therapeutics Announce Special Meetings of Stockholders
10 Feb 2021 //
BIOSPACE
Aytu BioScience Announces Closing of $28.75 Million Bought Deal Offering
15 Dec 2020 //
BIOSPACE
Aytu BioScience and Neos Therapeutics Announce Definitive Merger Agreement
10 Dec 2020 //
GLOBENEWSWIRE
Aytu BioScience and Neos Therapeutics Announce Definitive Merger Agreement,
10 Dec 2020 //
GLOBENEWSWIRE
Aytu BioScience Announces $10.0 Million Bought Deal Offering
10 Dec 2020 //
ACCESSWIRE
Aytu BioScience Announces Regulatory Approval of ZolpiMist(R) by Australian
30 Jul 2020 //
BIOSPACE
Aytu BioScience Announces Exclusive ZolpiMist(TM) License Aytu`s Oral Spray
08 Apr 2020 //
MARKETWATCH